Zhengye Biotechnology management commentary: Customer cost cuts drive 18.3% revenue decline in first half of 2026

• Zhengye Biotechnology Holding's management commentary reported first-half 2026 net loss narrowed to RMB 22.16 million, reflecting lower operating expenses.
• Revenue fell 18.3% to RMB 50.95 million as customers' sustained losses and cost-cutting reduced sales volumes, management said.
• Sales to the previously largest customer dropped to RMB 5.2 million from RMB 12.5 million as it began producing vaccines internally.
• Operating expenses declined to RMB 37.57 million, driven by lower employee compensation, professional fees and research spending, according to management.
• Operating cash outflow widened to RMB 16.81 million as uncollected receivables and inventory buildup weighed on working capital, management noted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-118931), on November 12, 2026, and is solely responsible for the information contained therein.